| Document |
Document Title |
|
JP2002536466A |
The present invention relates to a process for the production of cross-linked hyaluronic acid (HA) derivatives, in particular multiple, e.g. double cross-linked hyaluronic acid derivatives. The invention also provides novel cross-linked ...
|
|
JP2002536323A |
A method for the prevention or reduction in the severity of abscess formation in a human subject involves the use of a dilute solution of a polyanionic polysaccharide, preferably a solution of hyaluronic acid or carboxymethyl cellulose, ...
|
|
JP2002535967A |
IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
|
|
JP2002535360A |
The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wher...
|
|
JP2002534517A |
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1, 3-thiazolidines, 2-arylimino-2, 3, 4, 5-tetrahydro-1, 3-thiazines, 2-arylimino-1, 3-thiazolidin-4-ones, 2-arylimino-1, 3-thiazolidin-5-ones, and 2-arylimino-1, ...
|
|
JP2002534530A |
This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-alpha-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and preven...
|
|
JP2002533387A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533406A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533422A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533438A |
This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The pres...
|
|
JP2002533407A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533404A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533416A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002533405A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002532563A |
The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.
|
|
JP2002275096A |
To provide a method for reducing a tissue damage caused by ischemia, and to provide a kid used for the method.This method for reducing the tissue damage caused by ischemia comprises administering a medicinal composition containing an NHE...
|
|
JP3320748B2 |
Balanced pH, thermally-reversible and irreversible gels are useful vehicles for drug delivery and in the formation of a protective corneal contact lens. Thermally-irreversible gels are ideal materials for use as an ablatable mask for the...
|
|
JP2002527492A |
A method is provided for treatment or prevention of trauma-related damage in an organ or tissue of an individual which is based on administering to the individual liposomes which encapsulate either nucleic acid molecules comprising an ex...
|
|
JP2002526033A |
The present invention relates to polynucleotide and polypeptide molecules for zdint1, a novel member of the Disintegrin Proteases. The polypeptides, and polynucleotides encoding them, are believed to be cell-cell interaction modulating a...
|
|
JP2002526556A |
Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The formulations can also include suitable carr...
|
|
JP2002226399A |
To obtain a composition and to provide a method suitable for treatment or prophylaxis of inflammatory diseases, and to provide significant advantages compared with present procedures while treating problems accompanied with the present p...
|
|
JP2002523085A |
A composition of substantially purified pluripotent stem cells are positive both for fibroblast growth factor receptor (FGFR) and a phenotype indicative of a primitive state, such as CD34<+>, CD34<->lin<->, Thy-1<+>, AC133<+> or c-kit<+>...
|
|
JP2002522111A |
A method and apparatus for topical treatment of diseased tissue, including topical or systemic application of a PDT agent to diseased tissue, followed by topical application of light (24).
|
|
JP3287852B2 |
The present invention provides methods for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or deri...
|
|
JP2002154974A |
To provide a process for manufacturing a gas mixture, especially a gas mixture useful in a medical field and filling the gas mixture rapidly in a high reliability and effectively.This process for the dynamic manufacture and filling of a ...
|
|
JP2002154973A |
To provide a composition capable of effectively inhibiting bone growth associated with surgery in mammals such as human beings, and further to provide a method for producing the composition.A biocompatible anionic polymer is applied to a...
|
|
JP2002154972A |
To provide a composition capable of effectively inhibiting cell invasion associated with surgery in mammals such as human beings, and further to provide a method for producing the composition.This method for producing a medicine for inhi...
|
|
JP3285226B2 |
PURPOSE: To obtain a pharmaceutical preparation that contains a specific compound or its metabolite and is useful for treatment of the rejection of transplanted organs by the recipient. CONSTITUTION: This pharmaceutical composition conta...
|
|
JP2002513645A |
Solid, fibrous bioabsorbable hemostatic compositions containing a bioabsorbable polymer and a hemostatic compound, methods for making the hemostatic compositions, and methods for using the hemostatic compositions are disclosed.
|
|
JP2002138040A |
To provide a manufacturing method of a drug for inhibiting fibrosis at a lesion in mammals.Anionic polymers effectively inhibit cell invasion associated with unfavorable healing process and the inhibiting effect of the anionic polymers o...
|
|
JP2002512945A |
A pharmaceutical product which includes two-chambers, one having a buffered diluent and the other having acetylcholine. Upon mixing the chamber contents, a buffered efficacious acetylcholine product is prepared for post-surgical ophthlam...
|
|
JP2002505271A |
This invention provides an emulsion, e.g. microemulsion, pre-concentrate comprising a difficultly soluble active agent and a carrier medium. The active agent may e.g. be a cyclosporin or a macrolide.
|
|
JP2002505687A |
In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A2A receptors can reduce or prevent such restenosis...
|
|
JP2002504546A |
This invention relates to NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue...
|
|
JP2002503709A5 |
|
|
JP2002503709A |
The present invention relates to methods and compositions for the treatment of diseases by gene therapy. More particularly, it relates to the control of therapeutic gene expression by heat shock or stress promoters, the use of mixtures o...
|
|
JP2002503958A |
Die vorliegende Erfindung betrifft Aprotininvarianten mit einer Nettoladung von +3 bis -3 bei pH 7, wobei in der Bindungsregion der Aminosäurerest 10 Ser ist, der Aminosäurerest 13 Ile, Phe oder Leu ist, der Aminosäurerest 15 Arg ist,...
|
|
JP3239251B2 |
PURPOSE: To provide a cleaning liquid having isotonicity with living organ by adding an osmotic pressure keeping agent to an oxidation potential water. CONSTITUTION: An osmotic pressure keeping agent for adjusting the osmotic pressure 't...
|
|
JP2001329002A |
To provide a modified hyaluronic acid gel which can be obtained by using no crosslinking agent, is excellent in safety and biocompatibility and has controlled solubility, and to provide a medical material containing the same.A modified h...
|
|
JP2001521786A |
Isolated chondrocytes are propagated in the presence of a biological gel such as a fibrin gel to generate a cartilage matrix that firmly bonds together two adjacent cartilage pieces. A bonding composition containing the isolated chondroc...
|
|
JP2001520201A |
To reduce or prevent adhesions to or between organs, parts of organs or tissues, at a particular location in a mammal, the invention proposes to subject the mammal to a treatment which provides for reduced internalization and degradation...
|
|
JP3214116B2 |
PURPOSE: To obtain a perioperative infusion solution preparation capable of effectively correcting electrolytic balance in the surgical operation stage. CONSTITUTION: A perioperative infusion solution containing an electrolyte and a sacc...
|
|
JP3203382B2 |
PURPOSE: To provide an artificial-embolism forming polymer solution having relatively low viscosity, capable of being quickly clotted after being injected into a blood vessel so as to obstruct the blood vessel without directly damaging t...
|
|
JP2001511445A |
Certain retinoid derivatives, most or all of which are selective RXR retinoid agonists, have been found to be useful in the prevention or minimization of surgical adhesion formation.
|
|
JP2001213898A |
To provide a physiologically active peptide which has an integrin- activating action and can be utilized for curing wounds, repairing tissues after operations, improving obesity, or the like.This physiologically active peptide which comp...
|
|
JP2001206850A |
To obtain an ocular anagenesis inducer such as a cornea, the lens, a vitreous body and the like. The ocular anagenesis inducer comprises a hydrophilic polymer, as an effective component, mainly comprising an alkylene glycol unit or a vin...
|
|
JP2001510162A |
The invention comprises a composition for lubricating and separating membranes from adjacent membranes or membranes from adjacent cells or tissues comprising a hydrophobized polymer which is a biologically acceptable water soluble cation...
|
|
JP2001509519A |
The present invention relates to novel bioabsorbable polymeric compositions based upon AB polyester polyether or related diblocks and triblocks. Compositions according to the present invention may be used in medical applications, for exa...
|
|
JP3174400B2 |
PURPOSE: To provide a peritoneal lavage solution capable of effectively preventing the adhesion of organs after the closure of abdomen in abdominal operation. CONSTITUTION: The peritoneal lavage solution is an aqueous solution containing...
|
|
JP2001503739A |
A method for treating wounds including contacting a wound with an effective wound healing amount of bioactive glass and topical antibiotic and composition for the accelerated healing of wounds and burns including particulates of bioactiv...
|
